For the fiscal year ending March 2026, consolidated net sales reached 55,604 million yen (up 2.3% YoY), setting a new record high. Operating profit was 7,184 million yen (+11.2%), and net income attributable to owners of the parent was 5,596 million yen (+17.4%), achieving all-time highs. Increased overseas construction machinery sales and the effects of yen depreciation contributed to these results.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6364","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/6364-20260511-01.pdf","jir_short_summary":"For the fiscal year ending March 2026, consolidated net sales reached 55,604 million yen (up 2.3% YoY), setting a new record high. Operating profit was 7,184 million yen (+11.2%), and net income attributable to owners of the parent was 5,596 million yen (+17.4%), achieving all-time highs. Increased overseas construction machinery sales and the effects of yen depreciation contributed to these results.","jir_summary":"### Overview of Financial Performance\nFor the fiscal year ending March 2026, consolidated net sales amounted to a record 55,604 million yen (up 2.3% YoY), with profits significantly increasing driven by increased sales of overseas construction machinery and the effects of yen depreciation. Operating profit was 7,184 million yen (+11.2%), and net income attributable to owners of the parent was 5,596 million yen (+17.4%), maintaining a robust performance. Segment-wise, sales expansion overseas and proactive cost management led to an all-time high result.\n\n### Outlook and Impact on Shareholders\nThe earnings forecast for the fiscal year ending March 2027 anticipates some profit downside due to declining demand for domestic construction machinery and rising raw material costs, but sales are expected to remain firm supported by increased demand in the North American market. The annual dividend will be maintained at 72 yen, reflecting a commitment to shareholder return. Based on the medium-term vision, the company will continue expanding overseas operations and reducing costs, aiming for sustainable enhancement of corporate value.","jir_financial_highlights":"Net Sales: 55,604 million yen (YoY +2.3%)\nOperating Profit: 7,184 million yen (YoY +11.2%)\nNet Income Attributable to Owners of the Parent: 5,596 million yen (YoY +17.4%)\nTotal Assets: 65,690 million yen (Increase of 1,485 million yen)\nEquity Ratio: 68.5% (+4.8 percentage points compared to the previous year)","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #IRFinancialResults, #JapanStocks","jir_key_figures":"Net sales: 55,604 million yen (up 2.3% YoY)\nNet income attributable to owners of the parent: 5,596 million yen (up 17.4% YoY)\nEquity ratio: 68.5% (up 4.8 percentage points from the previous year)","jir_meta_title":"[TAKEDA PHARMACEUTICAL] FY2026 Financial Results | Record High Sales and Profits | May 2026","jir_meta_description":"Summary of Takeda Pharmaceutical Company Limited's FY2026 financial results. Achieved record sales, increased profits, ongoing overseas expansion and dividends. Includes future outlook.","jir_og_title":"[TAKEDA PHARMACEUTICAL] FY2026 Financial Results | Record High Sales and Profits | May 2026","jir_og_description":"Takeda's FY2026 financial results show record sales and profit growth. Overseas expansion and dividend continuation offer compelling value for investors.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[54353,55604],\\\"borderColor\\\":\\\"#36A2EB\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Profit\\\",\\\"data\\\":[6459,7184],\\\"borderColor\\\":\\\"#4BC0C0\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Profit\\\",\\\"data\\\":[4767,5596],\\\"borderColor\\\":\\\"#FF6384\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Composition\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Construction Machinery\\\",\\\"Industrial Machinery\\\"],\\\"datasets\\\":[{\\\"data\\\":[44128,10225],\\\"backgroundColor\\\":[\\\"#FF6384\\\",\\\"#36A2EB\\\"]}]}}\"}, {\"jir_chart_id\": \"profit_margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Net Sales\\\",\\\"Operating Profit\\\",\\\"Net Profit\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Profit Margin\\\",\\\"data\\\":[25.9,12.9,10.1],\\\"backgroundColor\\\":\\\"#4BC0C0\\\"}]}}\"}]","ir_related_company":17308,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-46339","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n